A rheumatologist who falsely diagnosed patients with arthritis was sentenced to prison and ordered to repay more than $28 million after billing Medicare, Medicaid, TRICARE and Blue Cross Blue Shield for unnecessary tests and treatments — a reminder that fraud can directly translate into patient harm through needless immunosuppression, procedures and imaging. The Department of Justice has also highlighted multiple recent schemes showing how quickly Medicaid/Medicare dollars can be exploited when documentation, referrals and utilization controls fail.

The Move

• Jorge Zamora-Quezada, a rheumatologist, was ordered to repay >$28 million and is serving about a decade in prison for falsely diagnosing arthritis and falsifying records to justify “unnecessary and expensive” treatments and testing.

• In Minnesota, the state House passed a bill to remove the Housing Stabilization Services (HSS) program from statute after a federal investigation found widespread fraud; costs ballooned from an estimated $2.6M/year to >$100M by 2024 before the program was shut down.

• Other DOJ-cited cases include: a $92.8M black-market diversion of HIV/AIDS drugs; >$41M in unnecessary gynecologic procedures; $328M billed for medically unnecessary genetic (DNA) tests, with $54M pocketed.

Why it Matters for Care

• False inflammatory arthritis diagnoses can expose patients to avoidable risks (e.g., steroids/DMARDs/biologics, infusion reactions, infection risk), plus cascades of imaging, labs and procedures that may not be clinically indicated.

• Clinicians may see downstream fallout: confused problem lists, “sticky” diagnoses that affect future care, and patient mistrust after they learn they were treated for a condition they didn’t have.

• For HIV/AIDS care, drug diversion and counterfeit/poorly handled meds can lead to treatment failure, toxicity, and resistance — even when the prescription is “filled” through normal pharmacy channels.

• Practice implication: tighten diagnosis documentation (objective criteria, differential, response-to-therapy logic), infusion/biologic prior-auth integrity, and internal audits for outlier utilization (high-volume injections/infusions, repeated imaging, high biopsy rates, etc.).

Between the Lines

• These schemes often exploit the same vulnerabilities: fee-for-service incentives, fragmented oversight across payers, and reliance on attestations/signatures rather than clinical evaluation.

• Recruiter-driven models (housing programs, urine testing, genetic testing) can create “patient supply chains” where beneficiaries are used as billing vehicles — sometimes with legitimate needs but fraudulent services.

• “Doctor chase” and falsified documentation shift risk onto clinicians whose names/signatures are used to legitimize orders, raising stakes for credentialing, supervision and order controls.

• Politically, high-profile fraud cases become arguments for tighter program rules and, at times, broader Medicaid/Medicare spending cuts — even when the fix should be targeted program integrity.

What to Watch

• Minnesota: whether the Senate advances the House bill removing HSS from statute, and what replacement guardrails (if any) are proposed for Medicaid-funded housing supports.

• Federal enforcement: additional DOJ/OIG actions tied to recruiter networks, lab testing mills, and medically unnecessary procedure volume outliers.

• Payers: more aggressive prior authorization and post-payment audits for infusions, imaging, biopsies and genetic testing — with potential spillover burden on legitimate rheumatology and primary care practices.

• Sentencing milestones: the gynecology case noted is awaiting sentencing (April), and the genetic testing case is awaiting sentencing after conviction (February).

Source: Reason